Compare CLRO & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLRO | EDSA |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3M | 12.8M |
| IPO Year | N/A | N/A |
| Metric | CLRO | EDSA |
|---|---|---|
| Price | $5.14 | $1.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 15.4K | ★ 34.5K |
| Earning Date | 11-14-2025 | 12-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,386,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 174.10 | N/A |
| 52 Week Low | $3.83 | $1.28 |
| 52 Week High | $21.00 | $4.49 |
| Indicator | CLRO | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 23.75 |
| Support Level | $5.25 | $1.43 |
| Resistance Level | $5.39 | $1.50 |
| Average True Range (ATR) | 0.30 | 0.08 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 2.96 | 4.59 |
ClearOne Inc is a communications solutions company, which is engaged in designing, developing, and selling conferencing, collaboration, streaming, and digital signage solutions for audio, video, and visual communication. It sells its commercial products to end-users predominantly through a network of independent distributors, who in turn sell its products to dealers, systems integrators, and other resellers. Its products include DSP mixers, amplifiers, Video walls, professional cameras, and professional microphones among others. Geographically the firm has its business presence across the United States and international markets.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.